TY - JOUR
T1 - Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients
AU - Del Bello, David
AU - Nagy, Fanny Ita
AU - Hand, Jonathan
AU - Khedemi, Rabea
AU - Lécluse-Barth, Julien
AU - Dieterich, Douglas
AU - Piroth, Lionel
N1 - Publisher Copyright:
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Purpose of review The aim of this review was to detail the current therapies and treatments for chronic hepatitis C virus in coinfected patients, focusing on HCV antiviral agents currently used in practice today or scheduled to enter the open market soon. Recent findings Several direct-acting antiviral (DAA) combinations show high sustained virologic response (SVR) rates in HIV/HCV-coinfected patients, which are often close to those observed in HCV-monoinfected patients. Most recommendations regarding treatment stem from trials with coinfected patients. However, data are lacking for some aspects of HCV-treatment in coinfection, so extrapolations must be made from data obtained predominately from monoinfected patients. Summary HIV/HCV-coinfected patients, who, not too long ago, had inferior outcomes in capturing SVR, now enjoy similar fates as the monoinfected patients. They should thus be prioritized for treatment, since HCV and liver disease have become major causes of morbidity and mortality in this population. However, potential drug-drug interactions between antiretroviral agents and DAAs have to be systematically anticipated before initiating HCV therapy.
AB - Purpose of review The aim of this review was to detail the current therapies and treatments for chronic hepatitis C virus in coinfected patients, focusing on HCV antiviral agents currently used in practice today or scheduled to enter the open market soon. Recent findings Several direct-acting antiviral (DAA) combinations show high sustained virologic response (SVR) rates in HIV/HCV-coinfected patients, which are often close to those observed in HCV-monoinfected patients. Most recommendations regarding treatment stem from trials with coinfected patients. However, data are lacking for some aspects of HCV-treatment in coinfection, so extrapolations must be made from data obtained predominately from monoinfected patients. Summary HIV/HCV-coinfected patients, who, not too long ago, had inferior outcomes in capturing SVR, now enjoy similar fates as the monoinfected patients. They should thus be prioritized for treatment, since HCV and liver disease have become major causes of morbidity and mortality in this population. However, potential drug-drug interactions between antiretroviral agents and DAAs have to be systematically anticipated before initiating HCV therapy.
KW - Direct antiviral agents
KW - HIV
KW - Hepatitis C virus
UR - http://www.scopus.com/inward/record.url?scp=84942933033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942933033&partnerID=8YFLogxK
U2 - 10.1097/COH.0000000000000182
DO - 10.1097/COH.0000000000000182
M3 - Review article
C2 - 26248121
AN - SCOPUS:84942933033
SN - 1746-630X
VL - 10
SP - 337
EP - 347
JO - Current Opinion in HIV and AIDS
JF - Current Opinion in HIV and AIDS
IS - 5
ER -